Work

HIV drug resistance: genotypic assays and their possible applications.

Year: 1998
Type: article
Abstract: Antiviral drug Key amino acid changes associated with resistance* Comments Zidovudine (AZT) M41L, D67N, K70R, L210W, T215Y, K219Q No cross resistance to any other inhibitors.For high level resistance(100-fold), at least three mutations, including 41 and 215 required.When 184 mutation present (combination therapy) resistance to AZT requires more than three mutations.Didanosine (ddI) K65R, L74V, V75T, M184V Codon 74 mutation suppresses the eVect of 215 AZT resistance mutation.Cross resistance to ddC.Zalcitabine (ddC) K65R, T69D, L74V, V75T, M184V Mutations conferring resistance to ddC rarely seen in clinical isolates and high level resistance has not been observed.Stavudine (d4T) V75T Codon 75 mutation, although documented by selection with a laboratory strain in vitro occurs infrequently in vivo.High level resistance has not been observed.Lamivudine (3TC) M184V/I/T Codon M184V mutation confers high level resistance (1000-fold), but the virus has a decreased replication rate.184 mutation suppresses the eVect of AZT 215 resistance mutation.In the majority of patients the 184 mutation resensitises virus to zidovudine.Abacavir (1592) K65R, L74V, Y115F, Q151M Preliminary data suggest that higher level phenotypic resistance is associated with a greater number of mutations and this determines virological response.Multiple nucleoside analogues A62V, V75I, F77L, F116Y, Q151M Mutation at 151 alone confers multidrug resistance.Observed in a significant proportion of individuals receiving long term therapy with two or more drugs.
Institution: Heartlands Hospital
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W2165326164
FWCI: 1.147
Cites: 14
Cited by: 12
Related to: 10